Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botulinum Injections for Lower Leg Anterolateral Chronic Exertional Compartment Syndrome
NCT05765071Recruiting
- Sponsor
- University of Calgary
- Start
- Jul 2025
- Primary completion
- Jun 2028
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, triple-blind trial of botulinum toxin type A in Chronic Exertional Compartment Syndrome (CECS) (2 arms), sponsored by University of Calgary. Primary endpoint: Change in maximum level of pain at time of painful sport activity at 24 weeks. Started Jul 2025; status: recruiting.
02
Drugs
botulinum toxin type A
03
Conditions
Chronic Exertional Compartment Syndrome (CECS)
Beyond the preview
Go deeper on NCT05765071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05765071.